Literature DB >> 20799257

Interval estimation of quantile ratios applied to anti-cancer drug screening by xenograft experiments.

Cheng Cheng1, Jianrong Wu.   

Abstract

The current practice in analyzing data from anti-cancer drug screening by xenograft experiments lacks statistical consideration to account for experimental noise, and a sound inference procedure is necessary. A novel confidence bound and interval procedure for estimating quantile ratios developed in this paper fills the void. Justified by rigorous large-sample theory and a simulation study of small-sample performance, the proposed method performs well in a wide range of scenarios involving right-skewed distributions. By providing rigorous inference and much more interpretable statistics that account for experimental noise, the proposed method improves the current practice of analyzing drug activity data in xenograft experiments. The proposed method is fully nonparametric, simple to compute, performs equally well or better than known nonparametric methods, and is applicable to any statistical inference of a 'fold change' that can be formulated as a quantile ratio.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20799257      PMCID: PMC3441185          DOI: 10.1002/sim.4038

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  Likelihood analysis for the ratio of means of two independent log-normal distributions.

Authors:  Jianrong Wu; Guoyong Jiang; A C M Wong; Xiang Sun
Journal:  Biometrics       Date:  2002-06       Impact factor: 2.571

2.  Smooth quantile ratio estimation with regression: estimating medical expenditures for smoking-attributable diseases.

Authors:  Francesca Dominici; Scott L Zeger
Journal:  Biostatistics       Date:  2005-05-04       Impact factor: 5.899

3.  Interval estimates for the ratio and difference of two lognormal means.

Authors:  Yea-Hung Chen; Xiao-Hua Zhou
Journal:  Stat Med       Date:  2006-12-15       Impact factor: 2.373

4.  The pediatric preclinical testing program: description of models and early testing results.

Authors:  Peter J Houghton; Christopher L Morton; Chandra Tucker; Debbie Payne; Edward Favours; Claire Cole; Richard Gorlick; E Anders Kolb; Wendong Zhang; Richard Lock; Hernan Carol; Mimi Tajbakhsh; C Patrick Reynolds; John M Maris; Joshua Courtright; Stephen T Keir; Henry S Friedman; Charles Stopford; Joseph Zeidner; Jianrong Wu; Tiebin Liu; Catherine A Billups; Javed Khan; Sherry Ansher; Jian Zhang; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2007-12       Impact factor: 3.167

5.  Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169.

Authors:  Thomas H Corbett; Kathryn White; Lisa Polin; Juiwanna Kushner; Jennifer Paluch; Chuan Shih; Cora Sue Grossman
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.